antifibrinolytic


Also found in: Encyclopedia, Wikipedia.

antifibrinolytic

 [an″te-, an″ti-fi″brĭ-no-lit´ik]
1. inhibiting fibrinolysis.
2. a substance that prevents fibrinolysis.

an·ti·fi·bri·no·lyt·ic

(an'tē-fī-brin'ō-lit'ik),
Denoting a substance that decreases the breakdown of fibrin (for example, aminocaproate.

an·ti·fi·bri·no·lyt·ic

(an'tē-fī-brin-ō-lit'ik)
Denoting a substance that decreases the breakdown of fibrin (e.g., aminocaproic acid).
References in periodicals archive ?
However, in 42% of cases, a combination of drugs was necessary, opting mainly for an antifibrinolytic agent and an attenuated androgen (only 4 men used attenuated androgens in combination).
(17,18) We set out to study whether or not the results of previous RCTs can be translated into a larger practice settings and among multiple centers and surgeons and to confirm which antifibrinolytic agent should be favored in corrective surgery for AIS.
Tranexamic acid [TA] being a lysine analog is one of the most extensively used antifibrinolytic agent that has proven to reduce bleeding and decrease allogeneic blood transfusions in major surgeries and trauma.
TABLE Facts about tranexamic acid * The dose is 1 g IV; it may be repeated once in 24 hours * Half-life is 2 hours * Clearance is renal--so do not use in patients with renal impairment * Antifibrinolytic activity usually lasts 7 to 8 hours * Tranexamic acid is contraindicated in patients with a history of thromboembolism in pregnancy * The drug is believed to be compatible with breastfeeding
Porte, "Efficacy and safety of antifibrinolytic drugs in liver transplantation: a systematic review and metaanalysis," American Journal of Transplantation, vol.
A Cochrane systematic review including two randomized controlled trials (RCTs) evaluating the effectiveness and safety of antifibrinolytic agents in hemoptysis of all causes was also published in 2012 and revised in 2016 [103].
The administration of antifibrinolytic agents blocks the formation of fibrin and is a high-grade alternative [4].
Current treatment options include bradykinin receptor antagonist icatibant, ecallantide, C1-esterase inhibitor (C1-INH) concentrate, progestin, and antifibrinolytic agent tranexamic acid (TA) [4-17].
Tranexamic acid is clinically used as a haemostatic agent because of its antifibrinolytic effect, through which it blocks lysine binding sites on plasminogen molecules [1].
[10] General measures include antifibrinolytic therapy, e.g.
In anovulatory bleeding with stable patient, PG synthetase inhibitors such as mefenamic acid and antifibrinolytic drugs tranexamic acid were used as the first-line therapy for control of blood loss.
[3] Studies have showed that antifibrinolytic therapy such as tranexamic acid, aminocaproic acid, recombinant factor VII, and platelet transfusions is the beneficial therapies for a patient with GT.